MannKind Corporation (NASDAQ:MNKD), which happens to be a top end company that focuses on discovery, development and commercialization of therapeutic products has made the much awaited announcement.
The provider’s board of directors has reached the decision to explore the financial and strategic alternatives for MannKind’s elaborate Technosphere-based pipeline candidates. This Technosphere platform is associated with a simple and needle-free administration, an ultra-rapid onset of action, improved bioavailability as well as the avoidance of hepatic metabolism.
In a bid to support the company’s strong desire and dedication to help patients, Locust walk will be seeking to find strategic investors and partners to non-dilutively advance the development of Technosphere-based therapies. This company has over the years channeled its financial resources in the commercialization of Afrezza. Some inside sources reveal that it is seeking alternative mechanisms that will help it fund more development programs for the Technosphere platform.
The Chief Medical Officer of MannKind Corporation, Raymond Urbanski when addressing a number of top news reporters said, “I am excited to collaborate with Locust Walk, who has extensive global experience in pharmaceutical partnering, to help bring our product candidates to market, such as Epinephrine Technosphere® for anaphylaxis, Trepostinil Technosphere® for pulmonary arterial hypertension, and Palonosetron Technosphere® for chemotherapy-induced nausea and vomiting.”
In a recent board meeting, one of the company’s top executives said that they were happy with the great progress they had made over the years in terms of discovering, developing and commercializing therapeutic products for patients diagnosed with health complications such as diabetes.
He went ahead to add that leveraging of the technological advancements as well as directing enough resources in the area of research has played a big part in getting the company where it currently stood.
The company urges all those persons that need to make follow ups on its progress to visit its website. In so doing, it will be easy for them to gain access to e-mail alerts which the company automatically issues whenever it gives its releases.
It is at the moment laying down strategies to engage in more research that will help develop more solutions to help the various patients globally.